AR and prostate carcinoma: Patient’s gender influences, indeed, the efficacy of immunotherapy in many solid tumors [72, 73], and combination of AR antagonist, enzalutamide and anti-PDL1 mAb exerts a remarkably antitumor effect in mouse model of castrate-resistant prostate cancer [19].